NEOVA Power Defense review: resolve the name before interpreting the numbers

Power Defense is presented as a serum

The current heading names Power Defense, and the adjacent subheading calls it an antioxidant serum with Copper Peptide Complex. The page also describes a lightweight gel texture. These statements identify the captured finished product, rather than an isolated trademarked ingredient.

The exact format matters because a claim concerning a complex is not automatically a result for the entire serum, and the serum’s other constituents remain part of its identity. The declared product name and format are evidence of how NEOVA presents it. They do not identify the composition of an inspected bottle or prove a batch-specific concentration.

The copper complex has a literal declared name

The highlight identifies Copper Peptide Complex through Bis[Tripeptide-1]Copper Acetate and GHK-Cu wording. The full list contains Bis (Tripeptide-1) Copper Acetate. Those entries can be reported as the manufacturer’s written descriptions, without treating the trademark as an analytical certificate.

The examined text does not establish the complex loading, pure active share, supplier dilution or assay method. A trademarked name also does not disclose every constituent amount in the finished serum. The grade-and-purity guide explains why an identity description and a verified quantitative specification are different records.

The highlighted and listed peptide names disagree

A separate highlight names Caprooyl Tripeptide-3, while the complete declaration names Caprooyl Tetrapeptide-3. The captured page contains both forms. This review preserves that discrepancy as unresolved rather than replacing one entry with an assumed correction.

The mismatch does not establish which ingredient an actual package contains or why the wording differs. It also does not by itself prove a formula change, a defective product or a mistaken concentration. It is an identity gap within the available record. The Naturium review offers a separate reading route for online declaration questions, without supplying a resolution for NEOVA.

Resolving that wording would require a relevant clarification or package record, rather than an editorial choice between the two names. Even such a clarification would answer the identity question first; it would not automatically quantify the copper complex or authenticate the outcome panel. Keeping the gaps separate prevents a future correction of one ingredient label from being mistaken for confirmation of every formulation and performance statement on the page. This review makes neither inference from the discrepancy.

The full list is still not a quantitative specification

NEOVA supplies a complete captured declaration containing the copper entry, other peptides and formulation ingredients. Even if the highlighted-name discrepancy were resolved, that list of names would not disclose an exact numerical recipe or independent copper-purity measurement. The unresolved identity question and missing quantities are distinct limits.

FDA’s US ordering explanation describes exceptions to simple descending-order assumptions, including ingredients at no more than one percent and color additives. The framework does not calculate Power Defense’s constituent amounts or verify a package’s compliance. List position cannot turn the trademarked complex into a measured copper percentage.

Seventy-one and seventy-four describe reported outcomes

The source panel states a 71% decrease in wrinkle count and 74% improvement in texture. These are the endpoint descriptions NEOVA gives in its clinical-study panel. They should not be rewritten as percentages of study participants or as the concentration of the copper complex.

The panel’s “Complete Clinical Study” text indicates another document, but that document was not read for this review. The examined panel does not identify the population, full methods, control conditions or the calculation behind each figure. The study-endpoint guide explains why those missing details matter to interpretation of a result.

The package caveat limits the current-list claim

NEOVA says formulations are refined and that website ingredient lists may vary from product packaging. That qualification belongs beside the online declaration. It does not automatically explain the Tripeptide-3/Tetrapeptide-3 discrepancy or establish which edition of a physical bottle matches either wording.

The source therefore leaves a version question as well as a numerical question. No package comparison or manufacturer clarification was obtained here. The current webpage can be described faithfully without converting a general refinement caveat into a documented reformulation event, and without assuming its clinical panel identifies every version that might have been sold.

The useful evidence question comes before a ranking

The record names a serum and a copper complex, discloses a complete list and reports two outcome figures. It also leaves the highlighted-name conflict, active quantities and complete-study details unresolved. A careful reading of the official source keeps all of those elements visible rather than using the largest percentage as the conclusion.

The Medik8 review examines a different version boundary, while the original source comparison organizes unlike product records. These links provide further questions to read, not a clinical rank. An unresolved name is a reason for precision, without becoming proof for or against a reader’s outcome.